Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity
- 312 Downloads
The purpose of this study was to analyze the postoperative systemic toxicity and procedure-related mortality (PRM) of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal surface malignancies (PSMs).
Patients and methods
A total of 242 (84 males/158 females) patients with PSM underwent 247 consecutive procedures. The mean age was 52 years (range 22–79). CRS was performed using peritonectomy procedures. The HIPEC technique through the closed abdomen was conducted with cisplatin (CDDP 25 mg/m2/l of perfusate)+mitomycin C (MMC 3.3 mg/m2/l perfusate) or CDDP (43 mg/l perfusate)+doxorubicin (Dx 15.25 mg/l perfusate) at 42.5°C. These dosages were reduced by 30% when the patient had received systemic chemotherapy before the CRS+HIPEC. Systemic toxicities were graded according to the NCI CTCAE v3 criteria.
G3-5 systemic toxicity rate was 11.7 % and adverse events were bone marrow suppression, 13; nephrotoxicity, 14; neutropenic infection, 2 and pulmonary toxicity, 1. Independent risk factors for G3-5 systemic toxicity after multivariate analysis were a dose of CDDP for HIPEC of 240 mg or more (OR 2.78, CI 95% 1.20–6.45) and CDDP+Dx schedule for HIPEC (OR 2.36, CI 95% 1.02–5.45). PRM was 1.2%.
CRS+HIPEC presented acceptable systemic toxicity and PRM rates. Independent risk factors for systemic toxicity were the CDDP+Dx schedule and CDDP dose for HIPEC.
KeywordsPeritonectomy Hyperthermic Intraperitoneal Chemotherapy Toxicity
Supported in part by grants from the AIRC (Associazione Italiana Ricerca sul Cancro).
- 4.Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22:3284–3292PubMedCrossRefGoogle Scholar
- 5.Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737–3743PubMedCrossRefGoogle Scholar
- 6.http://www.peritonealworkshop2006.com. Last access February 2007Google Scholar
- 9.Younan R, Kusamura S, Baratti D, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2005; 12(11):910–918PubMedCrossRefGoogle Scholar
- 10.Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006; 106(5):1144–1153PubMedCrossRefGoogle Scholar
- 11.Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49–58Google Scholar
- 12.Fujimoto S, Takahashi M, Kobayashi K, Kure M, Masaoka H, Ohkubo H, Isaka S, Shimazaki J. Combined treatment of pelvic exenterative surgery and intra-operative pelvic hyperthermochemotherapy for locally advanced rectosigmoid cancer: report of a case. Surg Today 1993; 23:1094–1098PubMedCrossRefGoogle Scholar
- 13.Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002; 94:492–499PubMedCrossRefGoogle Scholar
- 14.Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH. Analysis of morbidity and mortality in 60 patients with peritoneal. carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77:2622–2629PubMedCrossRefGoogle Scholar
- 17.Richard Sylvester. Planning cancer clinical trials. In: Buyse M E, Staquet Maurice J, Sylvester, Richard J. Cancer Clinical Trials. Methods and practice. First Edition. New York: Oxford University Press,1983:48–63Google Scholar
- 18.Fujimoto S, Takahashi M, Kobayashi K, Kure M, Masaoka H, Ohkubo H, Isaka S, Shimazaki J. Combined treatment of pelvic exenterative surgery and intra-operative pelvic hyperthermochemotherapy for locally advanced rectosigmoid cancer: report of a case. Surg Today 1993; 23(12):1094–1098PubMedCrossRefGoogle Scholar
- 23.Phelps JS, Gandolfi AJ, Brendel K, Dorr RT. Cisplatin nephrotoxicity: in vitro studies with precision-cut rabbit renal cortical slices. Toxicol Appl Pharmacol 1987 30; 90(3):501–512Google Scholar
- 28.Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10:863–869PubMedCrossRefGoogle Scholar
- 30.Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6:790–796PubMedCrossRefGoogle Scholar
- 32.Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M. Impact of the extent and duration of cytoreductive surgery on postoperative haematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005; 90(4):220–225PubMedCrossRefGoogle Scholar
- 33.Gianni L, Sessa C, Capri G, Grasselli G, Bianchi G e Vitali G. Farmaci Chemioterapici. In: Bonadona G, Robustelli Della Cuna G, Valagussa P. eds. Medicina Oncologica, 7th edn. Milano: Masson A MediMedia Company, 2003:583–676Google Scholar